ClinicalTrials.gg
CompletedNCT00904475Updated Feb 15, 2010

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

A Phase 4 interventional study of Lidoderm® and Lidoderm® in Chronic Low Back Pain, sponsored by Endo Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-15.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
257th of 623
102 · median 79
Started
2003
with 8 others
Phase 4
50 of 711
4 open now
Registered
121st of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 257th largest by enrollment of the 623 interventional ones that give a count, is one of 9 that started in 2003, is one of 50 in phase 4, and was the 121st registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

Patients with moderate to severe chronic Low Back Pain (LBP) despite current analgesic treatment participated in a Phase IV clinical trial to evaluate the analgesic efficacy of the lidocaine patch 5% compared to placebo in treating moderate to severe chronic LBP.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Were currently experiencing moderate/severe pain despite current analgesic treatment
  2. Had daily moderate-to-severe LBP for at least 3 months duration
  3. Had a mean daily pain intensity score of >6 on a 0 to 10 scale, with 0 being no pain and 10 being pain as bad as the patients have ever imagined (Question 5 of BPI) during the baseline week; patients had to complete daily diary assessments at least 5 of 7 days during the baseline week

Exclusion criteria

Exclusion Criteria:

  1. Had a history of greater than one back surgery, or one back surgery within 3 months of study entry
  2. Had severe spinal stenosis
  3. Had chronic back pain of >12 months duration with an undefined spinal diagnosis
  4. Had radicular symptoms with radiation into the thigh or below (i.e., knee, calf, foot, etc.)
  5. Had received an epidural /local anesthetic injection within 2 weeks prior to study entry
  6. Had received trigger point injections within 2 weeks prior to study entry
  7. Had received Botulinum Toxin Injections for LBP within 3 months prior to study entry
  8. Were taking a lidocaine-containing product that could not be discontinued while receiving study medication
  9. Were taking class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)
  10. Had received Lidoderm for LBP in the past
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    1- Lidoderm®

    Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain

    Drug: Lidoderm®

  • Placebo comparator
    2-Placebo

    Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain

    Drug: Lidoderm®

Interventions

  • Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.

    Also known as: Lidocaine patch 5%

  • Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.

    Also known as: Lidocaine patch 5%

06

What researchers measure

Primary outcomes

  1. Mean change in average daily pain intensity (BPI Question 5) from baseline week to the final week of treatment (primary endpoint)

    Time frame: Visit - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42)

Secondary outcomes

  1. Mean change from baseline to Week 2 and Week6/EOS in average daily pain intensity (BPI Question 5)

  2. Pain relief (BPI Question 8)

  3. Mean change from baseline to Week 2 and Week 6 in Pain Quality Assessment Scale (PQAS)

  4. Patient and Investigator Global Impression of Pain Relief at Week 6

  5. QoL: Change from baseline to Week 6 in pain interference with QoL (BPI Question 9) and Profile of Mood States (POMS)

  6. Safety assessments included AEs, discontinuations as a result of AEs, clinical laboratory tests, vital signs, physical examination, plasma lidocaine levels, dermal assessments and sking sensory testing

07

Study locations

6 sites
  • Birmingham, Alabama, United States
  • Hueytown, Alabama, United States
  • Phoenix, Arizona, United States
  • Mill Valley, California, United States
  • Allentown, Pennsylvania, United States
  • Salt Lake City, Utah, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a primary completion of Apr 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2009
First posted
May 19, 2009
Start
Apr 2003
Primary completionActual
Apr 2003
Last update
Feb 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00904475
First posted
May 19, 2009
Start date
Apr 2003
Primary completion
Apr 2003
Last update
Feb 15, 2010

Study contacts

Sr. Director
study director · Endo Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion